माइटोक्सैंट्रोन के इंटरैक्शन
हम जिन FDA लेबल और फैक्ट शीट को इंडेक्स करते हैं, उनमें माइटोक्सैंट्रोन के 34 इंटरैक्शन दर्ज हैं: 2 गंभीर, 9 मध्यम, 23 मामूली, और 0 ऐसे जिनमें लेबल बताता है कि कोई महत्वपूर्ण इंटरैक्शन नहीं है। नीचे की हर प्रविष्टि उस वाक्य को उद्धृत करती है जिस पर वह आधारित है। दवा का यह पेज एक शुरुआती बिंदु है, आपकी स्थिति के लिए कोई फ़ैसला नहीं।
लेबल से लिए गए इंटरैक्शन
गंभीर इंटरैक्शन (2)
When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)] . (फिंगोलिमोड लेबल, दवाओं के इंटरैक्शन)
Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (सोफोसबुविर और वेल्पाटासविर लेबल, दवाओं के इंटरैक्शन)
मध्यम इंटरैक्शन (9)
…(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (एल्ट्रोम्बोपैग लेबल, दवाओं के इंटरैक्शन)
When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS [see Warnings and Precautions (5.2) ]. (ओक्रेलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)
For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (टेरिफ्लुनोमाइड लेबल, दवाओं के इंटरैक्शन)
- डॉक्सोरूबिसिनमध्यम
Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (माइटोक्सैंट्रोन लेबल, चेतावनियां)
- डॉनोरूबिसिनमध्यम
Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (माइटोक्सैंट्रोन लेबल, चेतावनियां)
In a randomized comparative trial of mitoxantrone injection plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone injection had a cardiac event defined as any decrease in LVEF below the normal range, congestive heart failure (n = 3), or myocardial ischemia. (माइटोक्सैंट्रोन लेबल, चेतावनियां)
For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (लेफ्लुनोमाइड लेबल, दवाओं के इंटरैक्शन)
Anthracycline Antibiotics High doses of cyclosporine (e.g., at starting intravenous dose of 16 mg/kg/day) may increase the exposure to anthracycline antibiotics (e.g., doxorubicin, mitoxantrone, daunorubicin) in cancer patients. (साइक्लोस्पोरिन लेबल, दवाओं के इंटरैक्शन)
Among 112 patients evaluable for safety on the mitoxantrone injection + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. (माइटोक्सैंट्रोन लेबल, चेतावनियां)
मामूली ज़िक्र (23)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
• Prior treatment with an immunosuppressant (e.g., mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil). (नैटालिज़ुमैब लेबल, चेतावनियां और सावधानियां)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
In first-line comparative trials of mitoxantrone injection + cytarabine vs. daunorubicin + cytarabine in adult patients with previously untreated ANLL, therapy was associated with congestive heart failure in 6.5% of patients on each arm. (माइटोक्सैंट्रोन लेबल, चेतावनियां)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (माइटोक्सैंट्रोन लेबल, दवाओं के इंटरैक्शन)
आप जो कुछ भी लेते हैं, उस सबके साथ माइटोक्सैंट्रोन को जांचें। अपनी पूरी सूची जोड़ें; हर जोड़ी एक साथ जांची जाती है।
चेकर में खोलेंयह चिकित्सकीय सलाह नहीं है। गंभीरता लेबल के शब्दों को दर्शाती है, आपकी परिस्थितियों को नहीं। “गंभीर” चिह्न वाला संयोजन डॉक्टर की देखरेख में सामान्य बात हो सकता है, और “मामूली” चिह्न वाला संयोजन ऊंची खुराक पर मायने रख सकता है। फार्मासिस्ट से पूछें।